Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 30:14:551.
doi: 10.1186/s12879-014-0551-y.

Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial

Xavier Castellsagué  1 , Jorma Paavonen  2 , Unnop Jaisamrarn  3 , Cosette M Wheeler  4 , S Rachel Skinner  5 , Matti Lehtinen  6 , Paulo Naud  7 , Song-Nan Chow  8 , Maria Rowena Del Rosario-Raymundo  9 , Julio C Teixeira  10 , Johanna Palmroth  11 , Newton S de Carvalho  12 , Maria Julieta V Germar  13 , Klaus Peters  14 , Suzanne M Garland  15 , Anne Szarewski  16 , Willy A J Poppe  17 , Barbara Romanowski  18 , Tino F Schwarz  19 , Wiebren A A Tjalma  20 , F Xavier Bosch  21   22 , Marie-Cecile Bozonnat  23 , Frank Struyf  24 , Gary Dubin  25 , Dominique Rosillon  26 , Laurence Baril  27 ; HPV PATRICIA Study Group
Collaborators, Affiliations

Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial

Xavier Castellsagué et al. BMC Infect Dis. .

Abstract

Background: More information is needed about time between sexual initiation and human papillomavirus (HPV) infection and development of cervical precancer.

Methods: The objectives were to investigate the time between first sexual activity and detection of first cervical HPV infection or development of first cervical intraepithelial neoplasia (CIN), and associated factors in women from the double-blind, multinational, 4-year PATRICIA trial. PATRICIA enroled women aged 15-25 years with no more than 6 lifetime sexual partners. Women were randomized 1:1 to the HPV-16/18 AS04-adjuvanted vaccine or to control, but only women from the control arm who began sexual intercourse during the study or within 6 months before enrolment, and had no HPV infection detected before the recorded date of their first sexual intercourse, were included in the present analysis. The time between onset of sexual activity and detection of the first cervical HPV infection or development of the first CIN lesion was analyzed using Kaplan-Meier and univariate and multivariable Cox proportional-hazards models.

Results: A total of 9337 women were enroled in the control arm of PATRICIA of whom 982 fulfilled the required inclusion criteria for analysis. A cumulative total of 28%, 44%, and 62% of the subjects had HPV infection within 12, 24, and 48 months, respectively. The overall incidence rate was 27.08 per 100 person-years. The most common oncogenic types associated with 6-month persistent infection were HPV-16 (incidence rate: 2.74 per 100 person-years), HPV-51 (2.70), HPV-52 (1.66), HPV-66 (1.14), and HPV-18 (1.09). Increased infection risk was associated with more lifetime sexual partners, being single, Chlamydia trachomatis history, and duration of hormone use. CIN1+ and CIN2+ lesions were most commonly associated with HPV-16, with an overall incidence rate of 1.87 and 1.07 per 100 person-years, respectively. Previous cervical HPV infection was most strongly associated with CIN development.

Conclusions: More than 25% of women were infected with HPV within 1 year of beginning sexual activity. Without underestimating the value of vaccination at older ages, our findings emphasize its importance before sexual initiation.

Trial registration: clinicaltrials.gov: NCT00122681 .

PubMed Disclaimer

Figures

Figure 1
Figure 1
Subject disposition.
Figure 2
Figure 2
Risk of developing a first cervical HPV infection or lesion following first sexual intercourse. a. HPVI. b. 6MPI. c. CIN1+. d. CIN2+. Any oncogenic HPV type: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
See this image and copyright information in PMC

References

    1. World Health Organization: Human papillomavirus laboratory manual. First edition. In 2009 , [http://www.who.int/immunization/documents/WHO_IVB_10.12/en/]
    1. Koshiol J, Lindsey L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:123–137. doi: 10.1093/aje/kwn036. - DOI - PMC - PubMed
    1. Woodman CBJ, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357:1831–1836. doi: 10.1016/S0140-6736(00)04956-4. - DOI - PubMed
    1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. - DOI - PubMed
    1. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, Kurman RJ, Manos MM. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169:235–240. doi: 10.1093/infdis/169.2.235. - DOI - PubMed

Publication types

Associated data